bpc-157 human clinical trials evidence safety and the Difference Between an Gap and a Cover-Up: What the entire evidence base actually looks like, and the questions to ask next. — WellFounded bpc-157 human clinical trials evidence

In vitro and mechanistic studies (weakest for clinical conclusions) Cell culture studies showing peptides protecting retinal cells from various insults (oxidative stress, glucose toxicity, inflammatory cytokines, hypoxia)

The peptides under investigation, include: Nle-AngIV (Nle-Tyr-Ile-His-Pro-Phe) and its analogs such as D-Nle-YIH, acetyl-NleYIH, -amino butyric acid-YIH, NleYI-amide, and the primary focus, N-hexanoic-Tyr-Ile-(6) aminohexanoic amide (Dihexa)

Conversely, control group wounds were not completely epithelialized by day 21 [2]

I cannot tell you from a single case whether that is the peptide or the overall metabolic program the patient was on

The FDA added it to injectable semaglutide in January 2025, and it climbs the dose axis like everything else. Burning or tingling skin tracks the dose, not the weight lost, and an active-comparator study put the risk about twice that of another weight-loss drug. The mechanism is unsettled: the tempting "it is the drugs signaling arm" story is ruled out, because the strongest GLP-1 signaler in the class carries no such signal

Supplies Needed Plan based on an 816 week weekly protocol with gradual titration